Despite guidance that anti-Alzheimer's disease medications not be prescribed for individuals with mild cognitive impairment and no clinical trials demonstrating efficacy of these drugs, studies from the United States and France have reported their use among mild cognitive impairment patients. Information on the percentage of mild cognitive impairment patients in the United Kingdom being prescribed these medications is unknown. The objective of this study is to determine the proportion of patients in the United Kingdom with mild cognitive impairment who have been prescribed these anti-Alzheimer's disease medications. This study also plans to examine the time between first anti- Alzheimer's disease prescription and diagnosis of dementia, as well as the frequency of prescriptions during that time period, among individuals with mild cognitive impairment who were later diagnosed with dementia.
The main objective of this study is to determine the proportion of individuals in the UK with mild cognitive impairment who were prescribed anti-Alzheimer's disease medications. A secondary objective is to learn about the timing and frequency of the use of these medications among those who later develop dementia. This will be a descriptive analysis. The first objective will be accomplished by determining how many of the mild cognitive impairment patients were prescribed anti-Alzheimer's disease medications prior to either their first diagnosis of dementia or their end date in the database (whichever is earliest). Once this group is defined, the proportion of mild cognitive impairment patients receiving a prescription will be calculated. The secondary objective will be addressed by reviewing the subset of patients with mild cognitive impairment who also have a dementia diagnosis and received a prescription for an anti-Alzheimer's disease drug prior to their dementia diagnosis. Among these patients, the time between the first prescription for these drugs and the first dementia diagnosis will be measured. Descriptive statistics will summarize this time measurement. Similarly, descriptive statistics will also be used to examine the number of these prescriptions per individual during the same time window.
Use of anti-AD medications.
Lisa Vinikoor-Imler - Chief Investigator - Biogen
Lisa Vinikoor-Imler - Corresponding Applicant - Biogen
Li Li - Collaborator - Biogen
Michele Potashman - Collaborator - Biogen
Susan Eaton - Collaborator - Biogen